Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

Eur Heart J. 2013 Jun;34(23):1708-13, 1713a-1713b. doi: 10.1093/eurheartj/eht042. Epub 2013 Feb 20.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Aspirin / pharmacology
  • Benzimidazoles / pharmacology
  • Cardiovascular Diseases / drug therapy*
  • Clopidogrel
  • Dabigatran
  • Drug Interactions
  • Drug Therapy, Combination
  • Fibrinolytic Agents / pharmacology*
  • Humans
  • Piperazines / pharmacology
  • Platelet Aggregation Inhibitors / pharmacology
  • Prasugrel Hydrochloride
  • Proton Pump Inhibitors / adverse effects*
  • Purinergic P2Y Receptor Antagonists / pharmacology
  • Thiophenes / pharmacology
  • Ticagrelor
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / pharmacology
  • Warfarin / pharmacology
  • beta-Alanine / analogs & derivatives
  • beta-Alanine / pharmacology

Substances

  • Benzimidazoles
  • Fibrinolytic Agents
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Thiophenes
  • beta-Alanine
  • Warfarin
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticagrelor
  • Dabigatran
  • Adenosine
  • Ticlopidine
  • Aspirin